Diisopropylethylamine → 2-{4-(2-({(2-(4-Chlorophenyl)-1,3-thiazol-4-yl)methyl}sulfanyl)-3,5-dicyano-6-(pyrrolidin-1-yl)pyridin-4-yl)phenoxy}ethyl N-(tert-butoxycarbonyl)-L-leucinate

HRID 1968312ノート

反応式

HRID 1968312 の反応式
[C:1]([O:5][C:6]([NH:8][C@H:9]([C:14]([OH:16])=[O:15])[CH2:10][CH:11]([CH3:13])[CH3:12])=[O:7])([CH3:4])([CH3:3])[CH3:2].Cl.CN(C)CCCN=C=NCC.O.ON1C2C=CC=CC=2N=N1.C(N(CC)C(C)C)(C)C.[Cl:49][C:50]1[CH:55]=[CH:54][C:53]([C:56]2[S:57][CH:58]=[C:59]([CH2:61][S:62][C:63]3[C:68]([C:69]#[N:70])=[C:67]([C:71]4[CH:76]=[CH:75][C:74]([O:77][CH2:78][CH2:79]O)=[CH:73][CH:72]=4)[C:66]([C:81]#[N:82])=[C:65]([N:83]4[CH2:87][CH2:86][CH2:85][CH2:84]4)[N:64]=3)[N:60]=2)=[CH:52][CH:51]=1>CN(C=O)C.O>[C:1]([O:5][C:6]([NH:8][C@H:9]([C:14]([O:16][CH2:79][CH2:78][O:77][C:74]1[CH:73]=[CH:72][C:71]([C:67]2[C:66]([C:81]#[N:82])=[C:65]([N:83]3[CH2:84][CH2:85][CH2:86][CH2:87]3)[N:64]=[C:63]([S:62][CH2:61][C:59]3[N:60]=[C:56]([C:53]4[CH:52]=[CH:51][C:50]([Cl:49])=[CH:55][CH:54]=4)[S:57][CH:58]=3)[C:68]=2[C:69]#[N:70])=[CH:76][CH:75]=1)=[O:15])[CH2:10][CH:11]([CH3:12])[CH3:13])=[O:7])([CH3:3])([CH3:2])[CH3:4]

参加物

8

反応物 5

HCID 81531DiisopropylethylamineHCID 83170L-Leucine, N-((1,1-dimethylethoxy)carbonyl)-HCID 27239391,3-Propanediamine, N'-(ethylcarbonimidoyl)-N,N-dimethyl-, monohydrochlorideHCID 27960291-Hydroxybenzotriazole hydrateHCID 46847262Neladenoson

生成物 1

HCID 687646672-{4-(2-({(2-(4-Chlorophenyl)-1,3-thiazol-4-yl)methyl}sulfanyl)-3,5-dicyano-6-(pyrrolidin-1-yl)pyridin-4-yl)phenoxy}ethyl N-(tert-butoxycarbonyl)-L-leucinate

試薬・触媒・溶媒 2

HCID 962Water溶媒HCID 6228Dimethylformamide溶媒

実験手順

0.89 g (3.82 mmol) of N-(tert-butoxycarbonyl)-L-leucine were initially charged in 10 ml of DMF, and 0.81 g (4.18 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 0.80 g (5.23 mmol) of 1-hydroxy-1H-benzotriazole hydrate and 1.13 g (8.71 mmol) of N,N-diisopropylethylamine were added. The mixture was stirred until a clear solution had been obtained. 1.00 g (1.74 mmol) of 2-({(2-(4-chlorophenyl)-1,3-thiazol-4-yl)methyl}sulfanyl)-4-(4-(2-hydroxyethoxy)phenyl)-6-(pyrrolidin-1-yl)pyridine-3,5-dicarbonitrile was then added, and the mixture was stirred at room temperature for 18 h. The mixture was added to 300 ml of water. The residue formed was filtered off with suction and washed with 50 ml of water. The crude product was dissolved in 50 ml of dichloromethane. The aqueous phase was separated off and the organic phase was dried over sodium sulfate. Removal of the solvent under reduced pressure gave 1.37 g (100% of theory) of the desired target compound.

後処理

  1. customhad been obtained
  2. stirringthe mixture was stirred at room temperature for 18 h
  3. customThe residue formed
  4. filtrationwas filtered off with suction
  5. washwashed with 50 ml of water
  6. dissolutionThe crude product was dissolved in 50 ml of dichloromethane
  7. customThe aqueous phase was separated off
  8. dry with materialthe organic phase was dried over sodium sulfate
  9. customRemoval of the solvent under reduced pressure
  10. customgave 1.37 g (100% of theory) of the desired target compound

出典と根拠

ORDレコード
ord-be1371cb60e3413c8663e9ad7d48dd0d
出典データセット
uspto-grants-2013_04
特許番号
US08420825B2

反応ノート

読み込み中…